Presentations – 5th CEE meeting


PRE-CONFERENCE - Wednesday, 18 September 

 Khoo, Saye 2016 120x160Introductory lecture + questions
Saye Khoo, MD, PhD, University of Liverpool, United Kingdom

Fiona, Marra PhD

Mini Lecture - HIV/HCV coinfection
Fiona Marra, University of Liverpool, United Kingdom



Milosz Parczewski, MD, PhD

Case 1:  Multimorbidity + questions and discussion
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Poland


 Anca Streinu-Cercel, MD, PhDCase 2:  Woman with HBV/HCV coinfection + questions and discussion
(No permission to publish slides or video)

Anca Streinu-Cercel, MD, PhD, Carol Davila University of Medicine and Pharmacy, Romania


Ales Chrdle photo (002)Case 3: From Chemsex to intensive care, then back to Chemsex? + questions and discussion
(Not yet available)
Aleš Chrdle, MD, České Budějovice Hospital, Czech Republic





Day 1 - Thursday, 19 September 2019

 Session 1: Epidemiology of HIV and hepatitis in the CEE countries 

Milosz Parczewski, MD, PhD

Epidemiology of viral hepatitis infection and treatment in CEE countries
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Sczecin, Poland


 Epidemiology of HIV infection and treatment in CEE countries
(Not yet available)
Anca Streinu-Cercel, MD, PhD, National Institute of Infectious Diseases Matei Bals, Romania
 Ivanova, Elena 2018Feasibility and acceptability of HCV self-testing
(Not yet available)

Elena Ivanova, MD, PhD, FIND (Foundation for Innovative New Diagnostics), Geneva, Switzerland
 Session 2: Access to care

EECA: Are we lagging behind?
Sergey Golovin, ITPCru, St. Petersburg, Russia


Access to quality assured  (WHO prequalified) generic medicines in the region
Liudmyla Maistat, Medicines Patent Pool, Geneva, Switzerland


Mojca Maticic, MD, PhDAccess to key populations
Mojca Maticic, MD, PhD, University of Ljubljana, Slovenia


 Round Table Discussion 
 Session 3: HIV and Hepatitis co-infection

Management of HIV/HCV co-infection in Young Women
Vadim Rassokhin, MD, 1st St. Petersburg State Medical University "Acad. I.P. Pavlov", St. Petersburg, Russia
(Presentation given by E. Boeva)

 Abstract-Driven Presentations 
 The prevalence of mutations of the Hepatitis C virus, associated with drug resistance to inhibitors of protein NS5A among patients of the republic of Belarus
Elena Gasich, Belarus
 Session 4: PrEP

PrEP and STI testing in CEE: What are the barriers, what works?
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Sczecin, Poland


 Abstract-driven presentations 
 Persistence on HIV pre-exposure prophylaxis medication: A challenge in pre-exposure prophylaxis (PrEP) program in Georgia
(Not yet available)

Ekaterine Karkashadze, Georgia
 Virological efficacy of first-line regimens, resistance profile and factors influencing adherence to ART in clinical practice in Ukraine
Tetiana Kyrychenko, Ukraine
 Industry-sponsored symposium 
 Session 5: Linkage to care and management of treatment failure in HIV

Switching to second line HIV therapy
Pavel Khaykin, MD, MainFachArzt, Frankfurt, Germany



Raben, DortheIntegrated testing for HIV, hepatitis, and STIs
Dorthe Raben, MSc, CHIP, Copenhagen, Denmark



Day 2 - Friday, 20 September 2019

 Session 6: HIV and tuberculosis co-infection
 Management of TB and HIV infection
(Not yet available)

Daria Podlekareva, MD 
University of Copenhagen, Copenhagen, Denmark

The challenging TB case: clinical, virological and pharmacological considerations
(No permission to publish slides)
Jonathan Schapiro, MD, Sheba Medical Centre, Tel Aviv, Israel


  Abstract-Driven Presentations 
 Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)
Saulius Čaplinskas, Lithuania
 Uptake and outcomes of dolutegravir based antiretroviral therapy in Georgia
(Not yet available)

Nino Rukhadze, Georgia
 The new tendencies in HIV and HCV epidemics in central region of Ukraine
Tetiana Koval, Ukraine
 Session 7: Abstract-driven presentations
 Management of Hepatitis C in primary healthcare in the country of Georgia
Akaki Abutidze, Georgia
 HCV prevalence and associated factors among people who inject drugs (PWID): Baseline results of Georgian PWID cohort study
Ketevan Shermadini, Georgia
 Diversity of HIV-1 subtypes in Russia 2009-2019
Konstantin Gromov, Russia
 Outcomes for hepatitis B vaccination among HIV-infected adults in Georgia
Shorena Dvali, Georgia
 Epidemiology of hepatitis B viral infection in the republic of Belarus
Viktar Mitsura, Belarus
 Implementation of the State Program on elimination of viral hepatitis C in Ukraine: achievements and challenges
Kristyna Pronyuk, Ukraine
 High level of integrase strand transfer inhibitors drug resistance mutations in INSTIs failed HIV-1 CRF06_cpx infected patients in Estonia
(No permission to publish slides)
Merit Pauskar
 Session 8: Hot topics in HIV and hepatitis
 Treatment of Hepatitis B in Ukraine: What are the remaining challenges?
(Not yet available)

Olga Golubovska, MD, PhD, Bogomolets National Medical University, Kyiv, Ukraine

Carolynne, Schwarze-Zander, MDVaccinations for HIV patients: which vaccinations when and how?Carolynne Schwarze-Zander, MD, University of Bonn, Bonn, Germany


Ligita JančorienėHIV/HCV Co-Infection: Influence on risk for cancer and cardiovascular events, and impact of successful HCV cure
Ligita Jancoriene, MD, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania